GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07554859 by Genfleet Therapeutics (Shanghai) Inc., with a registry enrolment figure of 90 participants, started 2026-05-20 and due to reach its primary completion in 2027-04-30. Interventions recorded: ArmA:GFH375; Arm B:GFH375; Arm C:GFH375. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: the efficacy of GFH375 as monotherapy and in combination therapy. Lung eligibility wording from the registry: "Pathologically (histologically or cytologically) confirmed advanced (Stage IV) or locally advanced non-squamous non-small cell lung cancer that is not amenable to radical surgery or radiotherapy". Sites: China. No results are recorded here; the registry entry is the source.